FDA Approves Libtayo for Locally Advanced and Metastatic Basal Cell Carcinoma
The FDA has approved Libtayo for the treatment of patients with locally advanced and metastatic basal cell carcinoma (laBCC) who have previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate
